Ipilimumab and Its Toxicities: A Multidisciplinary Approach
Open accessAbstract
The treatment for metastatic melanoma has evolved significantly in the past few years. Ipilimumab, an immunotherapy, is now in mainstream oncology practice given that it has shown improved overall survival in randomized clinical trials. Other immune modulating agents, such as programmed death receptor-1 and programmed death receptor ligand-1 antibodies, are showing promise in early clinical trials. This manuscript will review ipilimumab and its most common side effects. Immune-related adverse events (irAEs) are important to recognize early, and their presentation, timing of onset, and general recommendations for workup and management will be reviewed. Assembling a multidisciplinary team, as well as thorough education of the patient, is recommended to optimize patient care.
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
CTLA-4 blockade with ipilimumab may cause immune-related adverse effects such as colitis and enterocolitis.
“Nevertheless, CTLA-4 as a negative regulator of T cell immunological responses, is implicated in autoimmunity prevention; therefore, its blockage with ipilimumab may cause immune related adverse effects (irAEs) such as colitis and enterocolitis [84].”
From Immune Checkpoint Inhibitors in Cancer Therapy (2022) · cites this paper as [84]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
The citation lists haven’t been fetched yet
References 56 · Cited by 320
Research works printed but not linked: 7
- Siegel R, Naishadham D, Jemal A. Cancer statis- tics, 2012. CA Cancer J Clin 2012;62:10 -29.
- Min L, Vaidya A, Becker C. Thyroid autoimmu- nity and ophthalmopathy related to melanoma bio- logical therapy. Eur J Endocrinol 2011;164:303- 307.
- Marx J, Hockberger R, Walls R. Rosen's Emer- gency Medicine, 7th ed. Philadelphia, PA: Mosby Elsevier, 2009:760.
- Carpenter KJ, Murtagh RD, Lilienfeld H et al. Ip- ilimumab-induced hypophysitis: MR imaging find- ings. AJNR Am J Neuroradiol 2009;30:1751-1753.
- Barnard ZR, Walcott BP, Kahle KT et al. Hypo- natremia associated with ipilimumab-induced hy- pophysitis. Med Oncol 2012;29:374 -377.
- Eckert A, Schoeffler A, Dalle S et al. Anti-CTLA4 monoclonalantibodyinducedsarcoidosisinametastatic melanoma patient. Dermatology 2009;218:69 -70.
- EDITOR'S NOTE: See the accompanying commentary on pages 658 -660. .
- Authors
- Fecher, L. A., Agarwala, S. S., Hodi, F. S., & Weber, J. S.
- Affiliations
- Abramson Cancer Center (US)
- St. Luke's Hospital (US)
- Dana-Farber Cancer Institute (US)
- Moffitt Cancer Center (US)
- Corresponding author
- Fecher, Leslie A.
- Venue
- The Oncologist
- Publisher
- Oxford University Press (OUP)
- Published
- 2013-06-01
- Volume
- 18
- Issue
- 6
- Pages
- 733-743
- ISSN
- 1083-7159 (ISSN-L)
- 1549-490X
- PMC
- PMC4063401
- OpenAlex
- W2152980179
- Cited by
- 320
- References
- 56
- Citations by year
- 2026: 7 · 2025: 10 · 2024: 15 · 2023: 10 · 2022: 14 · 2021: 14 · 2020: 58 · 2019: 22 · 2018: 32 · 2017: 40 · 2016: 33 · 2015: 38 · 2014: 24 · 2013: 3
- FWCI
- 3.45
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Licence
- academic.oup.com/journals/pages/open_access/funder_policies/chorus/standard_publication_model (vor)
- Locations
- The Oncologist (publishedVersion)
- Europe PMC (PubMed Central) (publishedVersion)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- Funders
- Bristol-Myers Squibb
- Topics
- Health Sciences › Medicine › Oncology › Cancer Immunotherapy and Biomarkers
- Health Sciences › Medicine › Oncology › Cutaneous Melanoma Detection and Management
- Life Sciences › Immunology and Microbiology › Immunology › Immunotherapy and Immune Responses
- Keywords
- ipilimumab, immune-related adverse events, metastatic melanoma, immune checkpoint inhibitors, immunotherapy toxicity, multidisciplinary care, patient education, adverse event management
- MeSH terms
- Ipilimumab, Antibodies, Monoclonal, Humans, Immunotherapy, Melanoma, Neoplasm Metastasis, Skin Neoplasms, Randomized Controlled Trials as Topic, Receptors, Death Domain, CTLA-4 Antigen, Drug-Related Side Effects and Adverse Reactions
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
